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A B S T R A C T
Hepatitis delta virus (HDV) is widely distributed and associated with fulminant hepatitis epidemics in
areas with high prevalence of HBV. Several studies performed in the 1980s showed data on HDV
infection in South America, but there are no studies on the viral dynamics of this virus. The aim of this
study was to conduct an evolutionary analysis of hepatitis delta genotype 3 (HDV/3) prevalent in South
America: estimate its nucleotide substitution rate, determine the time of most recent ancestor (TMRCA)
and characterize the epidemic history and evolutionary dynamics. Furthermore, we characterized the
presence of HBV/HDV infection in seven samples collected from patients who died due to fulminant
hepatitis from Amazon region in Colombia and included them in the evolutionary analysis. This is the
ﬁrst study reporting HBV and HDV sequences from the Amazon region of Colombia. Of the seven
Colombian patients, ﬁve were positive for HBV-DNA and HDV-RNA. Of them, two samples were
successfully sequenced for HBV (subgenotypes F3 and F1b) and the ﬁve samples HDV positive were
classiﬁed as HDV/3. By using all HDV/3 available reference sequences with sampling dates (n = 36), we
estimated the HDV/3 substitution rate in 1.07  103 substitutions per site per year (s/s/y), which
resulted in a time to the most recent common ancestor (TMRCA) of 85 years. Also, it was determined that
HDV/3 spread exponentially from early 1950s to the 1970s in South America. This work discusses for the
ﬁrst time the viral dynamics for the HDV/3 circulating in South America. We suggest that the measures
implemented to control HBV transmission resulted in the control of HDV/3 spreading in South America,
especially after the important raise in this infection associated with a huge mortality during the 1950s up
to the 1970s. The differences found among HDV/3 and the other HDV genotypes concerning its diversity
raises the hypothesis of a different origin and/or a different transmission route.
 2011 Elsevier B.V. 
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Hepatitis B virus (HBV) infection is one of the leading causes of
acute and chronic hepatitis disease in the world and is also
associated with liver cirrhosis and hepatocellular carcinoma (Fan
et al., 2010). It is estimated that 2 billion people are infected with
HBV, more than 350 millions of them are chronic carriers of this
virus (Lavanchy, 2005) and 15 millions of them are coinfected or
superinfected with HDV (Hadziyannis, 1997). The natural history of
chronic HBV infection appears to exhibit signiﬁcant geographical* Corresponding author at: Depto. Gastroenterologia, Faculdade de Medicina da
Universidade de Sa˜o Paulo. Av. Dr. Ene´as de Carvalho Aguiar, 500 segundo andar,
Pre´dio IMT 2, Sa˜o Paulo, SP. Brazil. Tel.: +55 11 30618218; fax: +55 11 30645932.
E-mail address: monica.viviana@usp.br (M.V. Alvarado-Mora).
1567-1348   2011 Elsevier B.V. 
doi:10.1016/j.meegid.2011.05.020
Open access under the Elsevier OA license.different behaviors what may be linked to differences in viral, host
and environmental factors (Hadziyannis, 2011).
HBV is classiﬁed into nine genotypes (HBV/A to HBV/I) where
each one differs from each other by 7.5–13% at the nucleotide level
(Kramvis et al., 2008; Yu et al., 2010). Speciﬁcally, HBV/F and HBV/
H genotypes are the most divergent viral genotypes in relation to
the others and HBV/F is characteristic of indigenous populations
from South America. HBV/F presents high frequency in several
American countries, especially those with Spanish colonization
(Alvarado Mora et al., 2011; Arauz-Ruiz et al., 2002; Devesa et al.,
2004, 2008; Santos et al., 2010), but it is also found in other sites
with Native American population, such as Inuits from Alaska
(Livingston et al., 2007) to the Brazilian Amazon rainforest
(Gomes-Gouveˆa et al., 2009). The presence of these genotypes in
the American countries appears to be very antique and much is
speculated about their origin (Alvarado Mora et al., 2011; Blitz
et al., 1998; Livingston et al., 2007).
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or as a superinfection in an HBV carrier. HDV has a negative-sense
circular RNA genome with about 1700 nucleotides that only
expresses delta antigen (Imazeki et al., 1990). HDV usually induces
a severe disease but its clinical manifestations are very broad,
ranging from asymptomatic cases to fulminant hepatitis (Bonino
et al., 1987; Hadziyannis et al., 1991). The virus is found worldwide
but is not uniformly distributed, as determined by seroprevalence
studies of anti-HD in HBsAg-positive patients (Rizzetto, 2000).
HDV genotypes are classiﬁed in eight different groups: genotype 1
is the most common genotype and is prevalent in Europe, Middle
East, North America and North Africa (Chao et al., 1990; Makino
et al., 1987; Shakil et al., 1997); genotype 2 prevails in Japan
(Imazeki et al., 1990), Taiwan (Wu et al., 1995) and Russia
(Ivaniushina et al., 2001); genotype 3 in the Amazon region in
South America (Casey et al., 1993); genotype 4 in Japan (Sakugawa
et al., 1999; Watanabe et al., 2003) and Taiwan (Wu et al., 1998)
and HDV genotypes 5 to 8 prevails in Africa (Le Gal et al., 2006).
In Colombia, few reports are available on HDV prevalence,
mainly showing its association to fulminant hepatitis outbreaks in
regions with intermediate or high HBV endemicity, particularly in
the Amazonas department, where high prevalence rates for anti-
HDV have been found among children younger than 4 years old
(Espinal, 1998). Furthermore, HDV has been described for more
than 50 years in Santa Marta region, in the north of Colombia,
where HBsAg seroprevalence was 4.7% (Ljunggren et al., 1985;
Buitrago et al., 1986). In another paper analyzing different
Colombian regions, HBsAg prevalence was 7.1%, 3.5% and 2.8%
in the Central region, in the Paciﬁc zone and in the Eastern region,
respectively (Prieto and Rojas, 2003). Moreover, in Colombia, HBV
genotype F3 is the most prevalent but genotypes A2, G, E and F1b
were also reported (Alvarado Mora et al., 2010, 2011).
The present study was conducted to obtain insight into the
molecular epidemiology and dynamics of HDV/3 genotype. We
also intended to estimate its nucleotide substitution rate and
the time of most recent ancestor (TMRCA). Also, we verify the
presence of HDV infection among 7 fulminant hepatitis cases of
hepatitis B identiﬁed in the Amazon Public Health Laboratory in
Leticia, Amazonas Department, Colombia. This is the ﬁrst study
reporting HBV and HDV sequences from the Amazon region of
Colombia.
2. Materials and methods
2.1. Study population
Seven HBsAg positive serum samples were collected between
January and December of 2007 in the Amazon Public Health
Laboratory in Leticia city, Amazonas, Colombia and stored at
70 8C. The age of the patients (ﬁve women and two men) ranged
from 17 to 39 years old. These samples came from inhabitants
with fulminant hepatitis from different small villages at the
Amazonas department, in Colombia. This protocol was approved
from Ethical Committees from the Pontiﬁcia Universidad Javeri-
ana, Bogota´, Colombia and University of Sa˜o Paulo Medical School,
Sa˜o Paulo, Brazil.
2.2. HBV DNA and HDV RNA ampliﬁcation
To avoid false-positive results, rigorous procedures used for
nucleic acid ampliﬁcation techniques were followed (Kwok and
Higuchi, 1989). HBV DNA extraction was carried out from 100 mL
of each serum sample using the acid guanidinium thiocyanate/
phenol/chloroform method (Chomczynski and Sacchi, 1987). HDV
RNA was extracted with same methodology from HBV DNA and
dissolved in 10 mL Milli Q water.Ampliﬁcation was performed by nested PCR covering a 737 bp
region corresponding to the S gene and a partial fragment of the
polymerase gene. The ampliﬁcation took place with the primers
described by Sitnik et al. (2004) and Gomes-Gouveˆa et al. (2009),
known as FBHS1 (50-GAGTCTAGACTCGTGGTGGACTTC-30; nt 244–
267) and FBHS2 (50-CGTGGTGGACTTCTCTCAATTTTC-30; nt 255–
278), and primers RADE1 (50-TGCRTCAGCAAACACTTGGC-30; nt
1175–1194) and RADE2 (50-TGRCANACYTTCCARTCAATNGG-30; nt
989–970).
For HDV, the partial delta antigen genomic region (403-
nucleotide fragment) it was ampliﬁed. For the detection of HDV
RNA, extracted RNA was previously denatured at 95 8C for 5 min
and then 20 mL of the reverse transcriptase was added with the
reverse primer 1302OD. Reaction mix was incubated at 37 8C for
60 min and stopped at 95 8C for 15 min. The ampliﬁcation of a
region of 403 bp was performed using the protocols described
previously by Casey et al. (1993) and Zhang et al. (1996). The
primers used were: 8531U (50-CGGATGCCCAGGTCGGACC-30; nt
853–871); 1302D (50-GGATTC ACCGACAAGGAGAG-30; nt 1322–
1303); HDV-E (50-GAAGGAAGGCCCTCGAGAACAAGA-30; nt 887–
910) and HDV-A (50-GAGATGCCATGCCGACCCGAAGAG-30; nt
1290–1267).
2.3. HDV and HBV sequencing
Ampliﬁed DNA was puriﬁed using ChargeSwitch1 PCR Clean-
Up Kit. Sequencing was performed in an ABI Prism1 377 Automatic
Sequencer (Applied Biosystems, Foster City, CA, USA) using
dideoxy nucleotide triphosphates (ddNTPs) containing ﬂuorescent
markers (Big Dye1 Terminator v3.1 Cycle Sequencing Ready Reaction
kit – Applied Biosystems, Foster City, CA, USA).
Quality of each electropherogram was evaluated using the
Phred-Phrap software (Ewing and Green, 1998; Ewing et al., 1998)
and consensus sequences were obtained by alignment of both
sequenced strands (sense and antisense) using CAP3 software on
the web page eletropherogram quality analysis (http://aspara-
gin.cenargen.embrapa.br/phph/).
2.4. Phylogenetic analyses
HBV and HDV sequences were genotyped by phylogenetic
reconstructions using reference sequences from HBV (n = 276) and
HDV genotype (n = 242) obtained from GenBank. Sequences were
aligned and edited using Clustal X (Thompson et al., 1997) and Se-
AL (available at: http://tree.bio.ed.ac.uk/software/seal/) software,
respectively. Bayesian phylogenetic analyses were conducted
using the Markov Chain Monte Carlo (MCMC) simulation
implemented in BEAST v.1.5.3 (Drummond and Rambaut, 2007).
HBV and HDV datasets were analyzed under relaxed uncorrelated
lognormal and relaxed uncorrelated exponential molecular clock
using the best model of nucleotide substitution (GTR + G + I)
chosen in MODELTEST (Posada and Crandall, 1998) and 10 million
generations were sufﬁcient to obtain the convergence of param-
eters. The molecular clock that best ﬁtted the data was chosen by
Bayes factor (BF) comparison. The maximum clade credibility
(MCC) tree was obtained from summarizing the 10,000 substitu-
tion trees after excluding 10% of burn-in using Tree Annotator
v.1.5.3 Drummond and Rambaut, 2007). Phylogenetic trees were
visualized in FigTree v.1.2.2 (available at: http://tree.bio.ed.ac.uk/
software/ﬁgtree/).
2.5. Evolutionary analysis for HDV/3
All HDV/3 sequences reported in Genbank and ﬁve additional
sequences reported in this study (n = 41) (25 from Brazil, 8 from
Venezuela, 6 from Colombia and 2 from Peru) were analyzed in this
Fig. 1. The(MCC) tree was estimated by Bayesian analysis of 242 hepatitis delta
virus strains. The posterior probabilities of the key nodes are depicted above the
respective nodes. Samples obtained from Colombia Amazon region (n = 5; marked
in green) were analyzed together with other worldwide strains. The Genbank
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5 from Venezuela, as the dates of sample collection were not
available from them. Bayesian Skyline Plot (BSL) was performed
under strict and relaxed uncorrelated lognormal molecular clock
using the best model of nucleotide substitution (GTR + G + I)
obtained in MODELTEST (Posada and Crandall, 1998).
3. Results
3.1. HBV and HDV genotyping
HBV and HDV PCR assays were carried out on the seven
samples that had been previously reported as positive for the
presence of HBsAg by an ELISA test (DiaSorin, Italy). In ﬁve of
them, it was possible to amplify the 737 bp fragment of HBV
genome and the 403 bp fragment of HDV genome. Sequencing of
all the ampliﬁed fragments was attempted but sequences with
good resolution were obtained for ﬁve HDV and two HBV
sequences. The two HBV sequences were typed by phylogenetic
analysis and they belong to genotype F (F1b and F3) (Fig. 1
supplementary material). All HDV sequences were classiﬁed as
genotype 3 (Fig. 1). HBV and HDV sequences were deposited at the
GenBank under accession numbers: EU287873–EU287874 and
EU287868–EU287872.
3.2. Evolutionary analysis for HDV/3
We obtained a substitution rate about 1.07  103 substitution/
site/year (s/s/y) for HDV/3 by running the BSL analysis with the
HDV/3 dataset with sampling dates. The evolutionary analysis
performed only on South American Amazon HDV/3 sequences
(n = 36) suggested that this genotype was circulating in South
America since the 1920s (95% high probability density (HPD) from
1821 to 1974). Furthermore, this genotype presented signals of
exponential growth from the end of the 50s until the end of the 70s
(Fig. 2), where after a reduction in infections was found. These
estimates correspond to the values obtained under the best-ﬁtted
molecular clock chosen by Bayes Factor comparison where the
relaxed uncorrelated exponential was the best molecular clock for
these analyses.
4. Discussion
4.1. HBV/F and HDV/3 co-infection
The two HBV sequences found in this study were classiﬁed as
subgenotypes F1b and F3. HBV/F3 was also reported as the most
prevalent in Bogota´, Colombia, followed by genotypes F1b, A2 and
G (Alvarado Mora et al., 2011). In Venezuela, subgenotypes F2 and
F3 were reported in Yucpa indigenous groups (Devesa et al., 2004;
Devesa and Pujol, 2007; Nakano et al., 2001).
All the 5 HDV isolates from Amazonas department, in southern
Colombia were classiﬁed as genotype 3. These results agree with
previous data describing that HDV/3 is the only genotype found in
the Peruvian Amazon Basin (Casey et al., 1993) and Western
Brazilian Amazon Basin (Gomes-Gouveˆa et al., 2009). There was
just one sequence from Colombia reported formerly (L22061): this
sequence was also HDV genotype 3 and was obtained from one
case from Santa Marta region (Ljunggren et al., 1985). It should be
stressed that the ﬁve positive strains for HDV were collected within
the Colombian Amazonas department but not in the same location.accession number, HDV genotype and geographic origin of each sequence are
indicated in the tree. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of the article.)
Fig. 2. Bayesian skyline (BSL) plot obtained from South American HDV/3 sequences (n = 36). The ﬁgure shows the superimposed median values of Ne.g through time. Time is
presented in years.
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they probably represent the commonest strain circulating in this
Colombian region (Fig. 1). A similarity of 100% is not completely
unexpected since it was already reported in Brazil a 100% of
similarity among viruses of patients infected with HDV/3, all of
them probably exposed to the same source of infection (Gomes-
Gouveˆa et al., 2009).
Two HDV/3 cases were co-infected with HBV/F3 and HBV/F1b,
respectively. Co-infection of HDV/3 with HBV/F is the most
frequent in the Amazon basin However, co-infection of HDV/3 with
HBV/A and HBV/D was previously reported in the same region in
Brazil (Gomes-Gouveˆa et al., 2009). In Venezuela, HDV genotypes 1
and 3 were reported and HDV/1 was associated with HBV/D while
HDV/3 was associated with HBV/F. The founding of HDV/1 in a
Yucpa Indian, that live in Sierra de Perija´, Zulia state, Venezuela,
probably reﬂects an transmission from European immigrants,
since, in the last century, these Indians have been the ones most in
contact with Amerindians communities (Quintero et al., 2001).
4.2. Substitution rate for HDV/3
The substitution rate estimated (1.07  103 substitutions per
site per year) in this work for HDV/3 was obtained using Bayesian
approach previously used for other viruses such as HBV, HCV and
GBV-C (Alvarado Mora et al., 2010, 2011; Romano et al., 2008,
2010; Zhou and Holmes, 2007). Other studies previously estimated
similar substitution rate for HDV, even though using very small
number of samples and distinct methods based on analysis of
similarity. The previously estimated evolutionary rates ranged
from 0.59  103 s/s/y to 3.0  102, which agrees with the data
obtained in this work (Chao et al., 1990, 1994; Imazeki et al., 1990;
Lee et al., 1992).
Using the sequences obtained from small populations living in
the Amazon region (n = 36), we estimated a TMRCA of about
85 years for the HDV genotype 3 strains circulating in these
populations. Since there are considerable variations on evolution-
ary rates previously reported and different substitution rates can
occur among distinct genotypes of the same virus (Alvarado Mora
et al., 2010, 2011; Romano et al., 2010; Zehender et al., 2008; Zhou
and Holmes, 2007), we did not evaluate the TMRCA for the deltagenotypes other than HDV/3 using the substitution rate estimated
in this study.
4.3. Dynamics of Hepatitis Delta genotype 3 in South America
Our evolutionary results agree with the previous data
supporting that hepatitis delta has been circulating in South
America since early 1930s, involved in many different outbreaks.
The ﬁrst report probably associated with this agent is known as
‘‘hepatitis de la Sierra Nevada de Santa Marta’’ (Ljunggren et al.,
1985; Buitrago et al., 1986). Another severe hepatitis outbreak
caused by this virus was also observed in the Labrea region on
Purus River, Acre, Brazil and was subsequently named Labrea
hepatitis or black fever (Bensabath and Dias, 1983). Such cases
have been reported since 1934 throughout the Amazon basin (Dias
and Coura, 1985).
The high frequency of HBV, together with the presence of HDV
markers, showed that these viruses represent the etiologic factors of
these diseases. The BSL also support the time of the increased
circulation of HDV in the northern region of South America by
showing an exponential growth between 1950s and 1970s. This
agrees with other studies that reported the presence of HDV
infection since 1950s as an unusual type of hepatitis in the Amazon
region of South America where, severe, often fatal, acute and chronic
type D hepatitis occurs among indigenous people in Brazil, Peru
Venezuela, and Colombia (Gomes-Gouveˆa et al., 2009; Bensabath
et al., 1987; Dias and Coura, 1985; Hadler et al., 1992; Popper, 1983).
Coincidentally, the period between 1950 and 1970 coincides with
the years were Brazilian and Colombian population growths reach
their maximum rates (http://www.census.gov/ipc/prod/wp96/
wp96005.pdf). The presence of HDV infection before this time
was much less relevant, probably because these Amazon regions had
a very low number of inhabitants, living in small villages dispersed in
the jungle, with very low contact between them, making difﬁcult the
spreading of this agent. Consequently, the increase in the viral
genetic variability observed in this period may be a consequence of
the increased number of susceptible hosts in this area, as well as the
rate of contact among them.
Different reasons are possibly related to the decrease in HDV
after 1970. First, it is possible to associate the slope down of HDV/3
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fulminant hepatitis, when HDV/3 infection was common (Buitrago
et al., 1986; Hadler et al., 1992; Popper, 1983). Second, in 1976 and
1979, Brazil implemented an epidemiological program in Sena
Madureira (Acre state) and in Boca do Acre counties (Amazon
state) to control both HBV and HDV infections (Bensabath and Dias,
1983). The most important fact associated with the decrease found
in HDV infection was the introduction of HBV vaccination
programs. Colombia and Brazil were the ﬁrst countries to
introduce universal vaccination against HBV in Latin America
(de la Hoz et al., 2005). In Brazil, vaccination started in September
1989 in Labrea city, where the infection was prevalent and a
signiﬁcant reduction in anti-HDV was reported thereafter (Braga
et al., 1998; Braga, 2004). In the Amazon basin, Colombia started
the vaccination program against HBV in 1992. Overall, after 2000,
vaccination was introduced in most Latin American countries
using different vaccination policies (Tambini et al., 1998).
Therefore, it is plausible that the decreasing rate of HBV spread
may be inﬂuencing the HDV growth. Unfortunately, since there are
few HBV genotype F sequences reported speciﬁcally from the
Amazon region in South America, it was not possible to reconstruct
the BSL for HBV/F of this region.
Finally, it is noteworthy that the ﬁrst treatment for HDV (IFN-a)
started in the mid 1980s (Rizzetto et al., 1986) and PEG-IFN-a was
implemented for the HDV treatment in 2006 (Erhardt et al., 2006;
Niro et al., 2006). Consequently, the use of effective treatment for
HDV may have had an impact on the HDV/3 spread, but it is hard to
evaluate its impact on populations resident in the Amazon
rainforest.
4.4. HDV/3 vs other HDV genotypes
The topology of the HDV MCC tree showed that HDV/3 is the
most divergent of the 8 HDV genotypes with a high signiﬁcant
posterior probability. This topology raises different questions in
relation of HDV/3 to the other genotypes: (1) did HDV/3
experience a distinct introduction in the human population? (2)
Is the route of transmission of HDV/3 different from the other
genotypes?
Concerning HDV origin, there are two main non self excluding
hypotheses for it: (1) as HDV shares similarities in terms of genome
structure and mechanisms of replication with plant viroids or
virusoids (Taylor and Pelchat, 2010), it was proposed that it might
have originated from RNA pathogens infectious from the vegetable
world; (2) HDV originated from host mRNA precursors with
ribozyme activity (Taylor and Pelchat, 2010).
Since there are different hypothesis for HDV origin, it will be
interesting to compare sequences from non-coding region of the
several different HDV genotypes to viroids, virusoids and self-
cleaving ribozymes sequences in eukariotyc organisms. The
differences found in the phylogenetic tree between HDV/3 and
the other genotypes raises the hypothesis that this genotype might
have a different origin from the remaining genotypes. Summing up
with its different geographical distribution, we might speculate a
particular event associated to its origin in the Amazon rainforest
(Rizzetto, 1990; Viana et al., 2005).
Concerning the possibility of different routes for each HDV
genotype, in industrialized countries, HDV in risk populations
include illicit drug users and individuals exposed to blood or
blood products (Pascarella and Negro, 2010). This is the case of
Asian countries where HDV/2 and HDV/4 genotypes are found in
intravenous drug addicts with HBV infection (Wedemeyer and
Manns, 2010). HDV generally is not considered a typically
sexually transmitted disease but in countries such as Taiwan
this route is the predominant way of transmission (Liaw et al.,
1990). For HDV/3, studies in the Amazon region on prevalence ofHBV and HDV showed that family members are reservoirs for
transmission of infection by HDV (Wedemeyer and Manns,
2010). In this way, the chances of contamination from an
extrafamilial source expressed by highly divergent isolates (Niro
et al., 1999) and the sequence similarity in most families units
indicate a single source of infection providing evidence that HDV
infection is probably mostly transmitted within the families
(Viana et al., 2005). This hypothesis has been supported with the
HDV distances between genotypes and within genotypes (Table
s1a and s1b) since the HDV/3 has the greatest distance when
compared with other genotypes but has the shortest distance
within of the sequences of the same HDV/3 group.
Finally, the geographical region where the HDV/3 is prevalent is
smaller than the other regions in the world where others delta
genotypes circulate. Consequently, it could also inﬂuence on the
low intra-genetic variability existing within HDV/3 in relation to
the other HDV genotypes.
5. Conclusions
In conclusion, the results obtained here show the importance of
continuing to undertake studies about the dynamics of HDV. Also,
this study shows the co-infection of HBV genotype F and HDV
genotype 3 in the Colombian Amazon region, similar to other
Amazon regions from Brazil and Venezuela. Finally, we suggest
that the measures implemented to control HBV transmission had
an impact on the control of HDV/3 spreading in South America,
especially after the important rise in this infection associated with
a huge mortality during the 1950s up to the 1970s. The differences
found among HDV/3 and the other HDV genotypes concerning its
diversity raises the hypothesis of a different origin and/or a
different transmission route.
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